ArticleDiagnostic pathology2026
Immunohistochemical expression of Stomatin-Like protein 2 and trophoblast cell surface antigen 2 in papillary thyroid carcinoma in comparison to other thyroid lesions.
Article in Diagnostic pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThyroid carcinoma is a common tumor affecting the Egyptian population accounting for 2% of newly diagnosed cases of cancer in Egypt yearly and constituting 7.73% of 5 year prevalence in Egypt. Stomatin-Like Protein 2 (SLP-2) and Trophoblast Cell Surface Antigen 2 (TROP-2) antibodies are both expressed in some types of thyroid carcinomas.
aimTo evaluate immunohistochemical expression of SLP-2 and TROP-2 in papillary thyroid carcinoma and other thyroid lesions, assess association of both immunohistochemical markers with variable demographic and histopathological parameters and assess the diagnostic utility of both markers in thyroid carcinomas. SUBJECTS AND
methodsThe current study is a cross-sectional study with analytical component, performed in the Pathology laboratory of Suez Canal University Hospital on 144 samples of formalin fixed paraffin embedded blocks of thyroid cases, including 79 cases of PTC and 65 cases of other thyroid lesions during the period from January 2016 to May 2019.
resultsSLP-2 and TROP-2 have shown positive expression in 91.1% and 82.3% respectively in PTC cases. Compared to positive expressions in 38.5% and 7.7% respectively in other thyroid cases. The positivity of both markers has a statistically significant association with PTC cases, compared to other thyroid lesions p-value < 0.05). The sensitivity of combined positively expressed markers is 79.75%, specificity is 98.46%, positive predictive value is 98.44, the negative predictive value is 80% and the test accuracy is raised to 88.19 for discrimination between PTC and other thyroid lesions. There was no statistically significant association between all histopathological parameters and the expression of SLP-2 and TROP-2.
conclusionsSLP-2 and TROP-2 may be promising diagnostic markers of PTC carcinoma. Further studies are needed to fully evaluate the prognostic significance of SLP-2 and TROP-2 expression in PTC and other thyroid lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.